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Abstract K-cell specific transcription of the glucagon gene is
mainly conferred by the glucagon promoter G1-element, while
additional elements G2, G3, and G4 have broad islet cell
specificity. Transcription of the glucagon gene has been shown to
be stimulated by Pax6 through binding to the glucagon gene
promoter G3-element. In this report, we show that Pax6
additionally binds the glucagon gene promoter G1-element and
forms a transcriptionally active complex with another homeo-
domain protein, Cdx2/3. Two distinct mutations in the G1-
element, that both reduce promoter activity by 85^90%, is shown
to eliminate binding of either Pax6 or Cdx2/3. Additionally,
Pax6 enhanced Cdx2/3 mediated activation of a glucagon
reporter in heterologous cells. We discuss how Pax6 may
contribute to cell-type specific transcription in the pancreatic
islets by complex formation with different transcription factors.
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1. Introduction
The cell speci¢c production of glucagon, insulin, somato-
statin, and pancreatic polypeptide by the four classical cell
types of the islets of Langerhans is regulated at the transcrip-
tional level [1^5]. The promoters of the glucagon, insulin, and
somatostatin genes are composed of a combination of posi-
tively and negatively acting cis-elements [6^12]. When iso-
lated, positively acting cis-elements confer tissue (islet) speci¢c
or cell-type (K, L, N) speci¢c expression [13^17]. Thus, the
glucagon gene G1-element confers K-cell speci¢c expression
[15,18] and the G2-, G3-, and G4-elements confer islet cell
speci¢c activity [15,19,20]. Many of the transcription factors
regulating the activity of the glucagon gene have been identi-
¢ed. A NeuroD/Beta2 containing complex binds the G4-ele-
ment [21], Pax6 binds the G3-element [22], and HNF-3L binds
to the G2-element [23]. Cdx2 (also known as Cdx3 [24] and
henceforth called Cdx2/3) that is expressed at low levels in
both exocrine and endocrine cells, and Brain-4 (Brn4) which
is expressed at high levels in K-cells have been surmised to
play a role in K-cell speci¢c glucagon gene activation through
binding to the G1-element [25^28]. In spite of their di¡erent
cell-type speci¢city the G1- and G3-elements contain a similar
sequence motif, the so-called PISCES (Pancreatic ISlet Cell
Enhancer Sequence) motif [13] suggesting that Pax6 might
also bind the G1-element. To begin to unravel the mechanism
by which these two elements confer di¡erent cell-type specif-
icity we analyzed the factors binding to these elements in a
glucagon-producing cell line. We found by antibody supershift
experiments that the major di¡erence between the two ele-
ments was the formation of a Cdx2/3-Pax6 complex speci¢c
for the G1-element. This complex was also formed in the
presence of recombinant Cdx2/3 and Pax6 protein. Small mu-
tations in the G1-element that are known to impair promoter
activity selectively abolished binding of either Cdx2/3 or Pax6.
Furthermore, Pax6 enhanced Cdx2/3 mediated activity of a
glucagon reporter lacking the G3-element in heterologous
cells. Together, these data suggest that the Cdx2/3-Pax6 com-
plex is functional and required for full promoter activity.
2. Materials and methods
2.1. Plasmids
pBAT7-Cdx3 [24] containing the hamster Cdx2/3 cDNA under con-
trol of the cytomegalovirus (CMV) promoter was a kind gift from M.
German, pSG5-Pax6 containing the quail Pax6 cDNA under control
of the SV40 promoter was a gift from S. Saule. The glucagon pro-
moter (3254 to +58) luciferase reporter plasmid p-254GLU-Luc was
constructed by replacing the SV40 promoter in the pGL2-Promoter
(Promega) with a 312 bp HincII-BamHI fragment cloned in p0CAT
[15].
2.2. Transfections
Transient transfection assays were done using Lipofectamine (Gib-
co-BRL) according to the manufacturer’s instructions. Brie£y, ap-
proximately 2.5U105 NIH-3T3 cells were seeded 4 to 8 h before trans-
fection in a 24-well tissue culture dish (Nunc). 150 ng of reporter
plasmid was cotransfected with 2 ng of the pRL-CMV renilla lucifer-
ase (Promega) as an internal standard, 5 ng of pSG5-Pax6, and 0.1 ng
of pBAT7-Cdx3. The same amount of empty expression vectors were
used for controls. All transfections were adjusted to a total of 500 ng
DNA per well using pBluescript SKII+ (Stratagene). 5^10 min before
adding transfection mix to the cells, cells were washed using 1 ml opti-
MEM per well. Cells were incubated overnight in a total volume of
500 Wl of transfection mix after which the same volume of normal
culture media with 20% serum was added. Cells were cultured for an
additional 24 h before harvesting. Luciferase and CAT activities were
measured as previously described [29]. Quanti¢cation of CAT assays
was done using a PhosphoImager (Molecular Dynamics). Dual luci-
ferase was measured using the Dual-Luciferase Reporter Assay Sys-
tem (Promega) and a TD-20/20 luminometer (Turner Designs). All
reporter activities were normalized to the internal standard.
2.3. Cell culture
NIH-3T3-B (obtained from R. Schumacher) and InR1-G9 cells [30]
were cultured in DMEM 1000 mg/l glucose containing 10% fetal calf
serum, 100 U penicillin/ml, and 100 Wg/ml streptomycin.
2.4. Cell extracts
Nuclear extracts were prepared by the method of Schreiber et al.
[31] except that bu¡er C contained 500 mM KCl instead of 400 mM
NaCl. Furthermore, leupeptin (1 Wg/ml), aprotenin (1 Wg/ml), 1 mM
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4-(2-aminoethyl) benzenesulfonyl £uoride hydrochloride (AEBSF),
and 1 mM sodium-orthovanadate were included. The recombinant
proteins were produced by transiently transfecting 2U106 NIH-3T3
cells in 6-well tissue culture dishes (Nunc) with 3^6 Wg of the relevant
expression plasmid. Whole cell extract was prepared as follows: Cells
were washed in PBS and lysed in whole cell extract bu¡er (2.5 mM
DDT, 20 mM HEPES pH 7.8, 10 mM KCl, 1 mM MgCl2, 10 mM
EGTA, 0.2% Triton X-100 supplemented with leupeptin (1 Wg/ml),
aprotenin (1 Wg/ml), AEBSF (1 mM), and 1 mM sodium-orthovana-
date) using 175 Wl per well. After shaking for 10 min at room temper-
ature, 33 Wl 2.1 M KCl and 46% glycerol bu¡er was added and
shaking was allowed to proceed for 10 min at room temperature.
The contents of the wells were adjusted to 15% glycerol using a
50% stock, collected and centrifuged at 20 000Ug for 10 min at
4‡C. The supernatant was collected and stored at 380‡C. Protein
content was measured using the Bradford assay (Biorad).
2.5. Antisera and electrophoretic mobility shift assays
The bg11 anti-Pax6 antiserum was a gift from S. Saule and has
been described previously [32]. Rabbit anti-Cdx2/3 antiserum 1277
was raised against the synthetic peptide NH3-SPPPQPSQPQ-
PGSLRSC-COOH (bold face indicates amino acids 262^277 of ham-
ster Cdx2/3) coupled to keyhole limpet hemocyanin as previously
described [33]. The anti-Cdx2/3 antiserum was determined to be spe-
ci¢c based on its ability to recognize Cdx2/3 but not Pdx1 or Pax6
expressed in NIH-3T3 cells. Oligonucleotide sequences for glucagon
probes are shown in Figs. 1 and 3. Five Wg of nuclear extract was used
in each standard EMSA. The reaction bu¡er contained 12.5% glycer-
ol, 30 mM Tris-HCl, 75^100 mM KCl, 20 mM NaCl, 1 mM MgCl,
20^50 Wg/ml poly-dIdC, 20^50 Wg/ml poly-dGdC, 2^4 Wg/ml herring
sperm DNA, 0.1% Nonidet NP-40 and, 3 mM DTT. For recombinant
proteins up to 10 Wg of whole cell extract was used and all reactions
were adjusted to the same protein concentration using extracts from
untransfected cells. Antisera were used at a 1/10 dilution in the pres-
ence of 15 mM NaN3 using 2^3 Wl per binding reaction as described
previously [29]. Binding reactions were separated on a 5% polyacryl-
amide gel as previously described [29]. The gels were dried and ana-
lyzed by autoradiography. Gel images were scanned using Adobe
Photoshop 3.0 and ¢gures prepared in Canvas 5.0.2.
3. Results
3.1. Pax6 and Cdx2/3 form a ternary complex with the
glucagon G1 promoter element
We initially con¢rmed that Pax6 bound to the G3-element
of the rat glucagon promoter. Electrophoretic mobility shift
assays (EMSA) using the G3 probe and InR1-G9 nuclear
extracts (Fig. 2A) revealed two complexes G3-A and G3-B.
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Fig. 1. Schematic representation of the rat glucagon promoter. Pax6
binding sites are indicated by hatched boxes and Cdx2/3 binding
sites as shaded boxes. Arrows indicate the orientation of the Pax6
binding sites. The sequence of the G1-element with Cdx2/3 binding
sites [26] and the G3-element is shown aligned with the Pax6 paired
domain consensus binding site [43].
Fig. 2. Pax6 and Cdx2/3 form a complex speci¢cally on the G1-element. A: Pax6 forms a single complex with the glucagon G3-element. 32P-la-
belled G3 oligonucleotide was incubated with nuclear extract from InR1-G9 glucagonoma cells and anti-Pax6 and anti-Cdx2/3 antiserum as in-
dicated. Arrows indicate the two speci¢c complexes G3-A and G3-B. G3-A is Pax6 immunoreactive. Arrowheads indicate supershifted com-
plexes. B: Pax6 and Cdx2/3 form a ternary complex with the G1-element. 32P-labelled G1 oligonucleotide was incubated with nuclear extract
from either InR1-G9 glucagonoma cells or recombinant Pax6 and Cdx2/3. Anti-Pax6 and anti-Cdx2/3 antisera were added as indicated. PI
equals a Pdx1 preimmune serum. Arrows indicate the G1-B1, G1-B2, and G1-B3 complexes. Open arrow indicates Cdx2/3 and Pax6 monomers.
The arrowhead indicates the Pax6-Cdx2/3 immunoreative complex (G1-B3). Grey arrows indicate supershifted complexes (note that supershifts
are identical with InR1-G9 extract and recombinant Pax6 and Cdx2/3). C: Lower exposure of the region boxed in B.
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The G3-A complex was identi¢ed as Pax6 since addition of a
Pax6 antiserum supershifted this complex (Fig. 2A). The iden-
tity of the G3-B complex remains unknown. We next estab-
lished that the G1-element also contained a Pax6 binding site.
Using the G1 probe (Fig. 1) we observed binding of two
prominent complexes G1-B1 and G1-B2 (Fig. 2B and C) as
well as a faint low mobility complex G1-B3 (Fig. 2B). The
intensity of these three bands was increased by the addition of
a preimmune serum (Fig. 2B, lane 2). Complexes G1-B2 and
G1-B3 were found to contain immunoreactive Pax6 (Fig. 2B
and C, lane 4). The G1-B2 complex formed with InR1-G9
extract migrated the same as recombinant Pax6 protein (Fig.
2B, lane 7) indicating that this complex represents a Pax6
monomer. Previously reported binding of Cdx2/3 to the G1-
element [26,27] prompted us to examine whether the G1-B3
complex also contained Cdx2/3. As seen in Fig. 2B, the G1-B3
complex was supershifted by anti-Cdx2/3 antiserum. A com-
plex of identical mobility was created when mixing recombi-
nant Pax6 and Cdx2/3, demonstrating that Pax6 and Cdx2/3
form a ternary complex with DNA on the G1-element (Fig.
2B, lane 9). In this experiment, we failed to detect the Cdx2/3
dimer reported by Laser et al. [26] due to the low amounts of
recombinant Cdx2/3 used. Higher amounts did produce a
Cdx2/3 dimer (see Fig. 3B). The supershift pattern generated
with the recombinant proteins was identical to the pattern
seen when using InR1-G9 extracts (Fig. 2B, compare lanes
3^5 with lanes 11^13). Using InR1-G9 nuclear extracts we
could not detect Cdx2/3 monomer binding to the G1 probe.
This was possibly due to a combination of low amounts of
Cdx2/3 in the extract and that Cdx2/3 monomeric binding was
obscured by other complexes.
3.2. The M9 and M11 mutations target Pax6 and Cdx2/3
binding, respectively
The e¡ects of mutations in the G1-element upon glucagon
promoter activity in InR1-G9 hamster glucagonoma cells have
been extensively studied by Philippe and co-workers [18,26].
The two most deleterious mutations found were: A single G
to T substitution at position 379 (M9, Fig. 3A) which re-
sulted in an approximately 90% decrease in promoter activity,
and a double AT to CC substitution at positions 373/374
(M11, Fig. 3A), that resulted in an 85% decrease in promoter
activity [18]. To examine for a possible correlation between
the e¡ect of these mutations on promoter activity and the
capability of Pax6 and Cdx2/3 to bind the G1-element we
synthesized oligonucleotides carrying these two mutations
and performed EMSA with recombinant Pax6 and Cdx2/3.
As shown in Fig. 3B, the M9 mutation abolished Pax6 bind-
ing while leaving Cdx2/3 binding una¡ected. Conversely, the
M11 mutation reduced Cdx2/3 binding while only a slight
reduction of Pax6 binding was observed. The residual Cdx2/
3 binding is expected as the M11 probe still harbors the distal
low a⁄nity Cdx2/3 binding site and as the mutation does not
completely abolish Cdx2/3 binding to the proximal site [26].
Formation of the Pax6-Cdx2/3-G1 ternary complex was di-
minished by both mutations (Fig. 3B).These data strongly
suggest that simultaneous binding of Cdx2/3 and Pax6 to
the proximal site is necessary for full promoter activity.
3.3. Pax6 potentates Cdx2/3 activation of a glucagon reporter
To further test whether Pax6 and Cdx2/3 were capable of
interacting functionally, we cotransfected a glucagon pro-
moter luciferase reporter construct (3254/+55, Fig. 1) with
Pax6 and Cdx2/3 expression vectors in NIH-3T3 cells and
assayed the reporter activity. To exclude any Pax6 mediated
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Fig. 3. Mutations that compromise glucagon promoter activity in
InR1-G9 cells reduce ternary complex formation. A: Synthetic oli-
gonucleotides used in EMSA. Mutations deviating from the wild-
type rat glucagon gene sequence are underlined. B: Binding of re-
combinant Cdx2/3 and Pax6 to wild-type or mutant G1 oligonucleo-
tides. Monomeric (Cdx2/3 or Pax6) and dimeric (Cdx2/3-Cdx2/3,
Cdx2/3-Pax6) complexes are indicated. Cdx2/3 binding to the M11
mutant is mediated by the distal binding site [26].
Fig. 4. Pax6 potentiates Cdx2/3 mediated transactivation of the rat
glucagon promoter. NIH-3T3 cells were transfected with 3254GLU-
luc or SV40-luc (pGL2 promoter) and co-transfected with the indi-
cated e¡ector plasmids or empty expression vectors as control. The
average of at least three independent experiments is presented. Error
bars indicate S.E.M.
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activity from the G3-element we used a reporter lacking the
core sequence of the G3 Pax6 binding site. Pax6 and Cdx2/3
were both capable of activating the reporter construct individ-
ually (2- and 8-fold, respectively, Fig. 4). However, inclusion
of both factors enhanced promoter activity 14-fold, more than
additively compared to the individual factors (Fig. 4). A con-
trol SV40 promoter was weakly activated by Cdx2/3 but not
by Pax6.
4. Discussion
Cdx2/3 has previously been implicated in the control of
glucagon promoter activity by binding to the glucagon G1
promoter element [26^28]. We now show that Cdx2/3, binding
to its proximal binding site, forms a functional complex with
Pax6 on the G1-element. We base our conclusion on several
observations. First, the two most deleterious mutations de-
scribed for the G1-element, M9 and M11 [18] selectively abol-
ish binding of Pax6 and binding of Cdx2/3 to its proximal site,
respectively. Second, both mutations abated the formation of
the Cdx2/3-Pax6-DNA ternary complex. Lastly, a glucagon
reporter construct lacking the upstream Pax6 binding G3-ele-
ment was activated by Cdx2/3 in heterologous cells and this
activity was enhanced by Pax6. Taken together these obser-
vations lead us to propose that simultaneous binding of Pax6
and Cdx2/3 to the G1-element is required for full activity of
the glucagon promoter. The partial overlap between the prox-
imal Cdx2/3 site and the Pax6 site is reminiscent of the com-
posite Pax5/Ets domain site (Fig. 5) found in the early B-
lymphocyte speci¢c gene mb-1 [34]. In both cases the Pax
protein and the second DNA binding protein seem to contact
the major groove of the DNA at the same nucleotides but
based on the published structures of the paired paired domain
[35], the antennapedia homeodomain [36], and the Ets domain
of PU.1 [37], the geometry of the paired domain and the
homeodomain/Ets domain binding to these partially overlap-
ping sites would place the DNA binding domains adjacent to
each other. In contrast to the recruitment of Ets proteins by
Pax5 on the mb-1 promoter we do not observe recruitment or
even co-operative binding between Pax6 and Cdx2/3. Instead,
the transcriptional co-operativity observed might result from
independent contacts with the basal transcriptional machi-
nery. The distal Cdx2/3 site is contained completely within
the Pax6 site (Fig. 5), but simultaneous binding to these two
sites is not observed. This is consistent with the relative in-
sensitivity of glucagon promoter activity to mutagenesis of
this Cdx2/3 site [18,26]. Moreover, structural considerations
(see Fig. 5) would seem to prohibit simultaneous binding of
Pax6 and of Cdx2/3 to the distal site due to steric hindrance
between the N-terminal arm of the Cdx2/3 homeodomain and
the Pax6 paired domain linker region, both contacting the
minor groove of the DNA. Interestingly, an additional exam-
ple of Pax6 binding simultaneously with another homeodo-
main protein is found on the somatostatin upstream enhancer
(SMS-UE). The SMS-UE is a composite enhancer element
that confers cell-type speci¢c activity to the somatostatin
gene [13,38]. In the case of the SMS-UE, Pax6 and Pdx1
bind to completely overlapping binding sites and together
contribute to the L/N-cell speci¢city of this enhancer element
(see accompanying manuscript).
A model proposing simultaneous binding of Cdx2/3 and
Pax6 is consistent with the observed reduced glucagon
mRNA level in vivo in the homozygous Sey1Neu mouse, which
lacks functional Pax6 protein [22]. Homozygous, Cdx2/3 mu-
tant mice do not survive the peri-implantation period and are
thus not informative concerning e¡ects on glucagon gene ex-
pression. However, heterozygotes show dosage dependent ef-
fects, evident as skeletal transformations. Additionally, the
heterozygotes develop multiple intestinal tumors [39]. These
mice would be interesting to examine for possible defects in
the pancreas. The presence of an additional Pax6 binding site
in the G3-element suggests that the glucagon gene might be
particularly sensitive to the lack of Pax6. Accordingly, the
severely reduced numbers of glucagon positive cells in the
pancreas of Pax6 mutant mice [22,40] might be explained if
disruption of the nucleosome structure of the glucagon gene is
a stochastic process where the chance of an open chromatin
structure is determined by the number of occupied binding
sites. Such a mechanism appears to regulate the activity of
the chicken erythroid speci¢c LA/O globin enhancer [41].
Cdx2/3 is expressed at very low levels in islet cells but does
not appear to show preferential expression in the K-cells
[25,26]. It would thus appear that additional factors are
needed to restrict glucagon expression to the K-cell. One
such factor could be the L-cell speci¢c protein Pdx1, which
has been reported to inhibit Cdx2/3 mediated activation of the
glucagon gene through a direct protein-protein interaction
[42]. Additionally, Brain-4 that is highly expressed in K-cells
within the islet has recently been shown to activate the gluca-
gon promoter through binding to the G1-element [25].
The presence of PISCES elements in L/N-cell speci¢c pro-
FEBS 21616 2-3-99
Fig. 5. Model of protein-DNA contacts in simultaneous binding of
Pax6 to paired domain consensus binding sites overlapping homeo-
domain and Ets domain binding sites. Protein-DNA contacts are in-
dicated as follows: m, minor groove contact; and M, major groove
contact. Predictions of the protein-DNA contacts were based on the
published three-dimensional structures of Drosophila paired [35] for
Pax5 and Pax6, Drosophila antennapedia [36] for Cdx2 and Pdx1,
and the Ets domain of PU.1 [37]. See main text for a discussion.
The arrow indicates the orientation and numbering of nucleotide
positions compared to the Pax6 paired domain consensus site [43].
Arrowheads indicate the equivalent position of the 20‡ bend in the
paired DNA binding site induced by paired binding. Placement of
Cdx2 contacts relative to its binding site supposes that the under-
lined nucleotides in the Cdx2 binding sites ATTTAT/CA represent a
degenerate ATTA core. Alternatively, a degenerate ATTA core can
be visualized as ATTTAT/CA, but this does not result in a su⁄-
ciently large change in spacing to avoid steric hindrance in the mi-
nor groove.
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moter elements of the insulin and somatostatin genes [13]
suggests that Pax6 might form di¡erent complexes on these
element. Indeed, we have found that Pax6 forms a functional
cell-type speci¢c complex with Pdx1 on the somatostatin up-
stream enhancer (see accompanying manuscript).
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